Download PDF
Drug Res (Stuttg) 2015; 65(04): 223-224
DOI: 10.1055/s-0034-1370942
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Abuse Potential of Carbamazepine for Euphorigenic Effects

S. H. Hosseini
1   Psychiatry and Behavioral Sciences Research Center, Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
,
A. Ahmadi
2   Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
› Author Affiliations
Further Information

Publication History

received 30 January 2014

accepted 10 February 2014

Publication Date:
25 March 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Euphoric effects following administration of CBZ alone have been never reported in any international journals and this is the first case report regarding to potential abuse of CBZ for euphoria. We hope this report will be a warning to physicians who will decide to prescribe CBZ, particularly in the patients who had a history of alcohol dependence as abuse potential of CBZ for euphoric effects has been frequently reported in the treatment of alcohol withdrawal.

Key word

euphoria - carbamazepine - drug abuse
 

  • References

  • 1 Huf R, Schain R. Long-term experiences with carbamazepine (Tegretol) in children with seizures. J Pediatr 1980; 97: 310-312
    CrossrefPubMedGoogle Scholar
  • 2 Wallace S. Carbamazepine in childhood seizures. Dev Med Child Neurol 1978; 20: 223-226
    PubMedGoogle Scholar
  • 3 Johnston MV, Freeman JM. Pharmacologic advances in seizure control. Pediatr Clin North Am 1981; 28: 179-194
    PubMedGoogle Scholar
  • 4 Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: A double blind comparison with phenytoin. Neurology 1977; 27: 1023-1028
    CrossrefPubMedGoogle Scholar
  • 5 Sillanpaa M. Carbamazepine: Pharmacology and clinical uses. Acta Neurol Scand Suppl 1981; 88: 1-202
    PubMedGoogle Scholar
  • 6 Goodman A, Gilman L. The pharmacologic basis of therapeutics. New York: 1980. Macmillan, Inc;
    Google Scholar
  • 7 Silverstein FS, Parrish MA, Johnston MV. Adverse behavioral reactions in children treated with carbamazepine (Tegretol). J Pediatr 1982; 101: 785-787
    CrossrefPubMedGoogle Scholar
  • 8 Stuppaeck CH, Whitworth AB, Fleischhacker WW. Abuse potential of carbamazepine. J Nerv Ment Dis 1993; 181: 519-520
    CrossrefPubMedGoogle Scholar
  • 9 Nutt DJ, Little HJ, Taylor SC et al. Investigating benzodiazepine receptor function in vivo using an intravenous infusion of DMCM. Eur J Pharmacol 1984; 103: 359-362
    CrossrefPubMedGoogle Scholar
  • 10 Shippenberg TS, Altshuler HL. A drug discrimination analysis of ethanol-induced behavioral excitation and sedation: The role of endogenous opiate pathways. Alcohol 1985; 2: 197-201
    CrossrefPubMedGoogle Scholar
  • 11 Post RM, Uhde TW, Ballenger JC. Efficacy of carbamazepine in affective disorders: implications for underlying physiological and biochemical substrates. In Emrich HM, Okuma T, Mueller AA. eds. Anticonvulsants in affective disorders. Elsevier; New York: 1984: 93-115
    Google Scholar
  • 12 Post RM. Mechanisms underlying the evolution of affective disorders: Implications for long-term treatment. Severe Depressive Disorders 1994; 23-65
    PubMedGoogle Scholar
  • 13 Sullivan G, Davis S. Is carbamazepine a potential drug of abuse?. J Psychopharmacol 1997; 11: 93-94
    CrossrefPubMedGoogle Scholar
  • 14 Weiss SRB, Post RM, Patel J. Differential mediation of the anticonvulsant effects of carbamazepine and diazepam. Life Sciences 1985; 36: 2413-2419
    CrossrefPubMedGoogle Scholar
  • 15 Elphick M, Yang JD, Cowen PJ. Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses. Arch Gen Psychiatry 1990; 47: 135-140
    CrossrefPubMedGoogle Scholar